reports
ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthc...
ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022 MENLO PARK, Calif. and SINGAPORE, April 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will present at the 21st Annual Needham Virtual Healthcare Conference. The conference will be held virtually from April 11 to 14, 2022. Presentation details Date: Thursday, April 14, 2022Time: 10:15 - 10:55am ETFormat: Compa...
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Re...
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement MENLO PARK, Calif. and SINGAPORE, April 01, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN) ("ASLAN" or the "Company"), announced today that on March 28, 2022, it received a written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with the US$1.00 minimum bid price requirement under the Nasdaq Listing Rules (the "Listing Rules"). Based on the closing bid price of ...
ASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From...
ASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From Eblasakimab Proof-of-Concept Study at the 2022 American Academy of Dermatology Annual Meeting MENLO PARK, Calif. and SINGAPORE, March 28, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the oral presentation of data from the completed Phase 1b multiple-ascending-dose (MAD) study that established proof of concept for eblasakimab (ASLAN004) in moderate-to-sever...
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financ...
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Global Phase 2b trial for eblasakimab in moderate-to-severe atopic dermatitis (AD) underway with topline data expected in the first half of 2023New CMO appointed, adding senior global pharma experience to the leadership team Company maintains strong operating position with US$90.2 million in cash and cash equivalents as of December 31, 2021, runway through late 2023Replays available for company-hosted A4 KOL series on AD landscape; next event to be held in the second quarter ME...
ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract o...
ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab Proof-of-Concept Study in Atopic Dermatitis for Oral Presentation at the 2022 American Academy of Dermatology Annual Meeting - Topline data from the eblasakimab Phase 1b multiple-ascending-dose study will be presented during the “Late-breaking Research: Clinical Trials” session at the 2022 American Academy of Dermatology Annual Meeting on March 26 MENLO PARK, Calif. and SINGAPORE, March 18, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutica...
ASLAN Pharmaceuticals Appoints Dermatology Veteran Dr Alex Kaoukhov as...
ASLAN Pharmaceuticals Appoints Dermatology Veteran Dr Alex Kaoukhov as Chief Medical Officer - Dermatologist with over twenty years of experience in senior biopharma roles in the US and Europe, including positions at Almirall, Allergan and Novartis- Strengthens leadership team as eblasakimab (also known as ASLAN004) moves into late-stage trials MENLO PARK, Calif. and SINGAPORE, March 15, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today an...
ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakima...
ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis The TRials with EblasaKimab in Atopic Dermatitis (TREK-AD) study will evaluate the efficacy and safety of ASLAN004, now known as eblasakimab, a potential first-in-class antibody targeting the IL-13 receptorThis dose-ranging study is expected to enroll approximately 300 patients and will evaluate 4 dose regimensTopline results are expected in 1H 2023 MENLO PARK, Calif. and SINGAPORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immun...
ASLAN Pharmaceuticals to Host New Episode in A4 KOL Series: Aspects of...
ASLAN Pharmaceuticals to Host New Episode in A4 KOL Series: Aspects of Atopic Dermatitis and ASLAN004 - Management to host the second webinar in ASLAN’s A4 series on Thursday, January 20, 2022, at 12:00pm ET MENLO PARK, Calif., and SINGAPORE, Jan. 18, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will host the second episode in its series of Key Opinion Leader (KOL) events on the emerging Atopic Dermatitis (AD) ...
ASLAN Pharmaceuticals to Present Additional Data From Aslan004 Proof-...
ASLAN Pharmaceuticals to Present Additional Data From Aslan004 Proof-Of-Concept Study at Two Upcoming Winter Dermatology Conferences - Data from Phase 1b dose escalation cohorts to be presented during the 2022 Winter Clinical Dermatology Conference, held in-person from 14-19 January, 2022, in Koloa, Hawaii - Data will also be presented as an encore presentation at the MauiDerm Conference, held in-person and virtually from 24-28 January, 2022, in Maui, Hawaii MENLO PARK, Calif. and SINGAPORE, Jan. 11, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-s...
ASLAN Pharmaceuticals to Present at H.C. Wainwright Bioconnect Confere...
ASLAN Pharmaceuticals to Present at H.C. Wainwright Bioconnect Conference 2022 MENLO PARK, Calif. and SINGAPORE., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, is scheduled to give a company presentation at the H.C. Wainwright Bioconnect Conference on January 10, 2022. The conference will be held virtually from January 10 to January 13, 2022. An on demand recording of the presentation will be ...
ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collabora...
ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration MENLO PARK, Calif. and SINGAPORE, Dec. 06, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of IQVIA Biotech, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organization for logistics related to decentralized clinical tri...
ASLAN Pharmaceuticals Announces Participation at Two Upcoming Virtual ...
ASLAN Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences MENLO PARK, Calif. and SINGAPORE, Nov. 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will be participating in fireside chats at two upcoming virtual health conferences. The details are as follows: Piper Sandler 33rd Annual Virtual Healthcare Conference Recorded discussion available: November 22...
ASLAN Pharmaceuticals to Participate in Fireside Chat at the 12th Annu...
ASLAN Pharmaceuticals to Participate in Fireside Chat at the 12th Annual Jefferies London Healthcare Conference 2021 MENLO PARK, Calif. and SINGAPORE, Nov. 10, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will participate in-person at the 12th Annual Jefferies London Healthcare Conference on November 17, 2021, at 1:00pm GMT. The conference will be held in-person November 16 and 17, 2021 and virtually Novembe...
ASLAN Pharmaceuticals Reports Third Quarter 2021 Financial Results and...
ASLAN Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update ASLAN004 met primary endpoint and key secondary efficacy endpoints in a Phase 1 Multiple-Ascending-Dose (MAD) trial in patients with moderate-to-severe atopic dermatitis (AD) On track to initiate Phase 2b 300-patient clinical trial for ASLAN004 in 4Q 2021 Company maintains strong operating position and cash runway through late 2023Replay available for company-hosted KOL event on AD landscape and to recap Phase 1 MAD data MENLO PARK, Calif. and SINGAPORE, Oct. 26, 2021 (GLOBE NEWSWIRE) -- ASLA...
ASLAN Pharmaceuticals Announces Scientific Collaboration With Dr Emma ...
ASLAN Pharmaceuticals Announces Scientific Collaboration With Dr Emma Guttman-Yassky on Identification of ASLAN004-Specific Biomarkers MENLO PARK, Calif. and SINGAPORE, Oct. 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced a collaboration with renowned inflammatory skin disease expert Dr Emma Guttman-Yassky, MD PhD, to conduct research that will continue throughout ASLAN’s Phase 2b program to identify and characterize the ef...
ASLAN Pharmaceuticals Announces KOL Event Series to Discuss Atopic Der...
ASLAN Pharmaceuticals Announces KOL Event Series to Discuss Atopic Dermatitis Treatment Landscape and ASLAN004 - Management to host the first in a series of KOL webinars beginning Monday, October 25, 2021, at 10:00am ET - First patient in global, 300-patient Phase 2b study of ASLAN004 on track for enrolment in 4Q 2021 MENLO PARK, Calif. and SINGAPORE, Oct. 18, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced it will host the fir...
ASLAN Pharmaceuticals Announces Expansion of Scientific Advisory Board...
ASLAN Pharmaceuticals Announces Expansion of Scientific Advisory Board With Appointment of Leading Global Experts in Dermatology and Immunology MENLO PARK, Calif. and SINGAPORE, Oct. 14, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointments of Dr Melinda Jennifer Gooderham, MSc MD FRCPC, Dr Jacob Thyssen, MD PhD DmSci, and Associate Professor Peter Foley, BMedSci MBBS MD FACD, as members of its Scientific Advisory Boa...
ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishin...
ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis - Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile - ASLAN004 achieved a statistically significant improvement (p
ASLAN Pharmaceuticals to Participate in the 2021 Cantor Virtual Global...
ASLAN Pharmaceuticals to Participate in the 2021 Cantor Virtual Global Healthcare Conference MENLO PARK, Calif., and SINGAPORE, Sept. 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to give a company presentation at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 9:20am ET. The conference will be held from September 27 to September 30, 2021. A live webcast of th...
ASLAN Pharmaceuticals Establishes Scientific Advisory Board Chaired by...
ASLAN Pharmaceuticals Establishes Scientific Advisory Board Chaired by Distinguished Dermatology Expert Dr Lawrence Eichenfield MENLO PARK. Calif. and SINGAPORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Dr Lawrence Eichenfield, MD, FAAD, as chair of its Scientific Advisory Board, comprising experts in dermatology and allergic disease from the United States, Canada, Europe, and Asia. Dr Eric S...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.